Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines

Margaretha A. Skowron, Guenter Niegisch, Philipp Albrecht, Gommert van Koeveringe, Andrea Romano, Peter Albers, Wolfgang A. Schulz, Michele J. Hoffmann*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number1680
Number of pages19
JournalInternational journal of molecular sciences
Volume18
Issue number8
DOIs
Publication statusPublished - Aug 2017

Keywords

  • urothelial carcinoma (UC)
  • cisplatin resistance
  • nuclear factor (erythroid-derived 2)-like 2 (NRF2)
  • sequestosome 1 (p62
  • SQSTM1)
  • Kelch-like ECH-associated protein 1 (KEAP1)
  • cytoprotection
  • glutathione
  • nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) pathway
  • hippo pathway
  • OVARIAN-CANCER CELLS
  • BLADDER-CANCER
  • OXIDATIVE STRESS
  • SIGNALING PATHWAY
  • CHEMOTHERAPEUTIC-AGENTS
  • TRANSCRIPTION FACTORS
  • ANTIOXIDANT RESPONSE
  • CROSS-TALK
  • BETA-TRCP
  • RESISTANCE

Cite this